A Controlled Clinical Study to Evaluate the Comparative Effect of Anuloma DS Tablet and Lactitol + Ispaghula Powder in Functional Constipation

: The International Classification of Diseases (ICD) has described constipation as decrease in normal frequencyof defecation accompanied by difficult or incomplete passage of stool and/or passage of excessively hard, dry stool (ICD10-CM-K59). Overall, the average prevalence of constipation in adults has been estimated as 16% worldwide (varies between0.7% and 79%); in adults aged 60 to 110 years, the prevalence has been estimated to be 33.5%. Objective: To evaluate andcompare the efficacy of tablet Anuloma DS and lactitol + ispaghula powder in constipation. Materials and methods: Sixty-twosubjects with constipation were divided into two groups: Group A with 32 subjects and Group B with 30 subjects. Group Areceived 1 Anuloma DS tablet at bedtime and Group B received lactitol + ispaghula powder 5 g at bedtime for 15 days.Results: Twenty-eight patients in Group A showed significant improvement in stool consistency of stool, whereas just8 patients showed improvement in consistency of stool in Group B. Twenty patients showed improvement in frequency ofstool in Group A, whereas only 3 patients showed this improvement in Group B. Twenty-nine patients in Group A reportedgood improvement in feeling after defecation compared to 9 patients in Group B. Pain in abdomen improved in 21 patientsin Group A versus 9 patients in Group B. Improvements were also seen in scores on the Constipation Assessment Scale,Patient Assessment Scale, and Quality of Life Questionnaire. Conclusion: Anuloma DS showed significant clinical benefitsin the treatment of constipation compared to lactitol + ispaghula powder.